PHARMACEUTICALS related term(s) Drugs

Addresses

State of the Union: President Trump, S576–S580 [30JA], H726–H730 [30JA]

Amendments

Dept. of HHS: ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), consideration (H. Res. 949), H5302 [20JN]

Drugs: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), consideration (H. Res. 787), H1709 [20MR]

——— prevent regulatory oversight from disrupting ability of emergency medical personnel to administer certain controlled substances (S. 916), S2881, S2882, S2884 [23MY]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), S6063 [6SE], S6193 [17SE], H5522, H5560, H5561, H5562, H5564, H5565, H5566 [22JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), consideration (H. Res. 949), H5302 [20JN]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (H. Res. 905), H4300 [22MY]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), S6062 [6SE], S6179 [17SE]

Medicare: prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), S6030, S6033 [4SE]

Taxation: include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), consideration (H. Res. 1012), H7104 [24JY]

Articles and editorials

Opioid Crisis Foretold, H5111 [13JN]

Pelosi Pulled Strings To Let Dying Dallas Lawyer Baron Try Experimental Cancer Drug, H1708 [20MR]

Bills and resolutions

Business and industry: clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers (see H.R. 7324), H10269 [17DE]

——— prohibit biological product manufacurers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market (see S. 3792), S7926 [19DE]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 3792), S7926 [19DE]

CDC: carry out certain activities to prevent controlled substances overdoses (see H.R. 5812), H3976 [15MY]

Centers for Medicare & Medicaid Services: compel manufacturers to correct inaccurate classification data reported to Medicaid rebate program (see H.R. 5712), H3833 [8MY]

——— provide for an action plan to prevent opioid addictions and enhance access to medication-assisted treatment (see S. 2769), S2484 [26AP] (see H.R. 5590), H3505 [24AP]

Colleges and universities: designate institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing (see H.R. 5568), H3441 [18AP]

Comprehensive Addiction and Recovery Act: reauthorize and expand (see S. 2456), S1243 [27FE] (see H.R. 5311), H1651 [15MR]

DEA: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (see H.R. 5483), H3209 [12AP]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (see S. 2659, 2661), S2120 [12AP]

——— amend certain regulations so that practitioners may not administer more than 3 days’ medication to a person at one time when administering narcotics in order to relieve acute withdrawal symptoms (see H.R. 5770), H3929 [10MY]

——— clarify process for denying, revoking, or suspending a registration to manufacture, distribute, or dispense a controlled substance (see H.R. 5267), H1542 [13MR]

——— deem drugs or other substances that act as opioid mu receptor antagonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 5298), H1651 [15MR]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse (see S. 2535), S1629 [12MR]

——— establish a national clearinghouse for all orders of controlled substances and require such orders pass through a database to identify suspicious orders and notify suppliers before orders are filled (see S. 3282), S5423 [26JY] (see H.R. 6600), H7723 [26JY]

——— improve systems for identifying diversion of controlled substances (see S. 2837), S2643 [14MY]

——— make publicly available online a report on the sale of controlled substances and controlled substance analogues over the Internet (see H.R. 5021), H1177 [14FE]

——— provide grants to certain States to increase participation in drug take-back programs (see S. 2645), S2075 [11AP] (see H.R. 5628), H3705 [26AP]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 2838), S2678 [15MY] (see H.R. 6491), H7154 [24JY] (see H.R. 6779), H8169 [12SE]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 2493), S1338 [5MR] (see H.R. 6702), H7870 [5SE]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (see S. 2561), S1765 [15MR]

Dept. of Defense: authorize use of certain funds for combating opioid trafficking and abuse (see H.R. 5546), H3440 [18AP]

——— develop a strategy to recruit and retain mental health providers and direct military departments to develop medication monitoring programs (see H.R. 6712), H7870 [5SE]

——— establish a prescription drug monitoring program for Armed Forces members (see H.R. 5591), H3505 [24AP]

——— prevent overprescription of opioids to TRICARE recipients by limiting duration of initial prescriptions (see H.R. 6165), H5362 [20JN]

Dept. of HHS: allow delivery of medical supplies by unmanned aerial systems (see H.R. 7395), H10586 [21DE]

——— authorize grants to health centers to expand access to evidence-based substance abuse treatment services (see H.R. 5456), H3095 [10AP]

——— award grants to train health care professionals to treat opioid addiction and other substance use disorders using technology-enabled models (see S. 2606), S1947 [22MR]

——— clarify intent, enhance integrity, and protect and expand 340B discount drug program to meet the needs of the opioid drug crisis (see H.R. 6071), H5093 [12JN]

——— clarify requirements for receiving certain grants through the National Mental Health and Substance Use Policy Laboratory (see S. 2626), S1948 [22MR]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments (see S. 2516), S1452 [7MR] (see H.R. 5197), H1476 [7MR] (see H.R. 5558), H3441 [18AP]

——— conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for certain Medicare enrollees (see H.R. 5582), H3451 [23AP]

——— consider Margaret R. Pardee Memorial Hospital in Hendersonville, NC, as a covered entity for purposes of the 340B drug discount program (see H.R. 7266), H10168 [12DE]

——— consider State analysis and sharing of prescription drug monitoring program data in determining prescription drug monitoring program grants to States (see S. 2451), S1219 [26FE]

——— develop a joint action plan to reduce single use drug waste and better manage costs relative to drug vial sizes and drug delivery systems (see H.R. 5867), H4209 [17MY] (see H.R. 6142), H5284 [19JN]

——— develop guidance on pain management and prevention of opioid use disorder for hospitals receiving payments under Medicare (see H.R. 5699), H3833 [8MY] (see H.R. 5774), H3934 [11MY]

——— enhance efforts to address antibiotic resistance (see S. 2469), S1286 [28FE]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (see H.R. 6082), H5151 [13JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), consideration (see H. Res. 949), H5283 [19JN]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (see H.R. 5795), H3975 [15MY]

——— ensure medications are affordable through increasing transparency, spurring innovation, and protecting competition (see S. 3411), S6038 [5SE]

——— establish a grant program to create comprehensive opioid recovery centers (see S. 2589), S1947 [22MR] (see H.R. 5327), H1697 [19MR]

——— establish a moratorium on new enrollment of disproportionate share hospitals into the 340B discount drug program and require basic data reporting (see S. 2312), S187 [16JA]

——— establish a technical expert panel for purposes of evaluating use of opioid-related quality measures under Medicare (see H.R. 5779), H3935 [11MY]

——— establish community action opioid response grant program (see S. 2636), S2040 [10AP] (see H.R. 5124), H1333 [27FE]

——— establish grant program to prevent student and student athlete opioid misuse (see H.R. 5992), H4738 [1JN]

——— establish grant program within the Substance Abuse and Mental Health Services Administration to create peer support recovery networks (see S. 2657), S2120 [12AP]

——— establish Office of Drug Manufacturing to manufacture certain generic drugs in order to reduce prices, increase competition, and address shortages in the prescription drug market (see S. 3775), S7790 [18DE] (see H.R. 7348), H10336 [19DE]

——— establish Prescription Safety Alert System to combat prescription drug abuse by collecting, maintaining, and providing to dispensers patients’ prescription and dispensing history (see H.R. 6688), H7776 [28AU]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (see S. 3680), S7241 [29NO]

——— extend floor on area wage index under inpatient prospective payment system and provide eligibility for discounted drug prices under 340B drug pricing program to certain sole community hospitals (see H.R. 5498), H3209 [12AP]

——— include additional covered recipients for transparency reports required of manufacturers of opioids (see S. 3565), S6770 [10OC]

——— issue guidance relative to expedited approval of certain drugs (see H.R. 5806), H3976 [15MY]

——— issue guidelines for prescribing naloxone (see H.R. 5926), H4692 [23MY]

——— make available on Centers for Medicare & Medicaid Services website opioid prescribing guidance for certain Medicare beneficiaries and update such guidance periodically (see H.R. 5777), H3934 [11MY]

——— make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants and expand use to include methamphetamine abuse (see H.R. 5140), H1340 [1MR]

——— nullify certain contractual provisions prohibiting or penalizing a pharmacist’s disclosure of availability of equivalent alternative drugs or methods of purchasing less expensive drugs (see H.R. 5343), H1727 [20MR]

——— prohibit price gouging in the sale of drugs by requiring pharmaceutical companies to provide justification for price increases and penalize such companies if increases are deemed unreasonable (see S. 3754), S7586 [13DE]

——— provide for certain user fees under the 340B drug discount program (see H.R. 6240), H5815 [27JN]

——— provide for opioid quality measures development and a technical expert panel on reducing surgical setting opioid use and data collection on perioperative opioid use (see H.R. 5774), H3934 [11MY]

——— provide for public disclosure of charges for certain hospital and ambulatory surgical center treatment episodes (see H.R. 6508), H7685 [25JY]

——— provide grants for eligible entities to provide technical assistance to outlier prescribers of opioids (see H.R. 5796), H3975 [15MY]

——— provide grants to State alcohol and drug agencies to use recovery coaches in hospital emergency rooms (see S. 2609), S1947 [22MR]

——— provide guidance to States regarding Federal reimbursement for services and treatment for substance use disorders under Medicaid using telehealth services (see S. 2904), S2835 [22MY] (see H.R. 6778), H8169 [12SE]

——— provide guidance to States relative to Medicaid items and services for non-opioid pain treatment and management (see S. 2911), S2835 [22MY]

——— provide research on, and recommendations for, opioid prescribing practices for pregnant women (see H.R. 5646), H3741 [27AP]

——— provide the Dept. of Justice certain notifications of improper prescribing of controlled substances under the Medicare program (see H.R. 7369), H10510 [20DE]

——— publish data relative to prevalence of substance use disorders in the Medicaid beneficiary population and treatment of substance use disorders under Medicaid (see S. 2912), S2835 [22MY]

——— reauthorize, improve, and make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants (see S. 2437), S1164 [15FE]

——— report on extent to which certain Medicare Advantage plans include supplemental health care benefits designed to treat or prevent substance use disorders (see H.R. 5725), H3884 [9MY]

——— require certain disproportionate share hospital (DSH) covered entities under the 340B drug discount program to submit reports on low-income utilization rates of outpatient hospital services furnished by such entities (see H.R. 5598), H3505 [24AP]

——— require prescribers to complete continuing medical education courses on potential dangers and risks of prescribing opioids (see H.R. 5581), H3451 [23AP]

——— require States to operate drug management programs for at-risk beneficiaries (see H.R. 5808), H3976 [15MY]

——— support endemic orphan fungal disease research, incentivize valley fever vaccine development, and discover new antifungal therapies and diagnostics (see H.R. 6562), H7721 [26JY]

——— update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling (see H.R. 5473), H3146 [11AP]

Dept. of Homeland Security: establish a narcotic drug screening technology pilot program to combat illicit opioid importation (see S. 3047), S3601 [11JN]

Dept. of Justice: make grants to, and enter into agreements with, State and local governments for programs to provide medication-assisted treatment to individuals incarcerated in the jurisdiction who are addicted to opioids (see H.R. 7079), H9438 [19OC]

——— provide grants for drug disposal sites (see H.R. 5557), H3441 [18AP]

——— reauthorize Comprehensive Opioid Abuse Grant Program (see H.R. 6029), H4979 [7JN]

Dept. of Labor: establish an Advisory Committee on Opioids and the Workplace (see H.R. 5892), H4284 [21MY]

Dept. of Veterans Affairs: ensure that certain medical centers have physical locations for disposal of controlled substances medications (see H.R. 6848), H8737 [20SE]

——— improve Medical Surgical Prime Vendor program by using multiple regional prime vendors and medical professionals with relevant expertise to develop the medical-surgical formulary (see S. 3737), S7431 [11DE] (see H.R. 5418), H3052 [29MR]

——— report on opioid prescribing rates of physicians of the Veterans Health Administration and conduct pain management training for physicians with highest rates of opioid prescribing (see S. 2819), S2623 [10MY] (see H.R. 5829), H3977 [15MY]

Diseases and disorders: facilitate effective research on, and treatment of, neglected tropical diseases through coordinated domestic and international efforts (see S. 3212), S4951 [12JY]

——— recognize value of pre-exposure prophylaxis medication as an effective prevention tool in combating HIV, support research and usage of such medication, and ensure effective HIV prevention outreach (see H. Res. 960), H5648 [25JN]

Drugs: address the opioid crisis (see S. 2680), S2141 [16AP]

——— allow for more flexibility relative to medication-assisted treatment for opioid use disorders and protect confidentiality of substance use disorder patient records (see H.R. 5807), H3976 [15MY]

——— authorize employees of a hospice program to handle controlled substances in the residence of a deceased hospice patient to assist in disposal (see H.R. 5041), H1211 [15FE]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (see H.R. 5247), H1541 [13MR]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), consideration (see H. Res. 787), H1697 [19MR]

——— develop and disseminate best practice guidelines for using data collected by prescription drug monitoring programs to identify drug diversion and abuse (see H.R. 6608), H7723 [26JY]

——— encourage development and use of new antimicrobial drugs in order to treat antibiotic-resistant infections (see S. 3787), S7926 [19DE]

——— enhance competition for prescription drugs by increasing ability of Dept. of Justice and FTC to enforce existing antitrust laws relative to biologic and biosimilar products (see H.R. 6478), H6649 [23JY]

——— ensure equitable distribution of resources to address opioid drug abuse epidemic (see H.R. 5109), H1333 [27FE]

——— establish an interagency task force to improve Federal response to families impacted by substance abuse disorders (see H.R. 5891), H4284 [21MY]

——— impose a fee on opioid manufacturers to fund an increase in drug addiction treatment capacity (see S. 3711), S7319 [5DE]

——— improve medical research on marijuana (see H.R. 4825), H552 [18JA]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment (see S. 2711), S2321 [19AP]

——— improve oversight of new opioids and education of prescribers, limit availability of addictive painkillers, strengthen prescription drug monitoring, and establish drug disposal programs (see S. 2729), S2342 [23AP] (see H.R. 5865), H4209 [17MY]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 5634), H3705 [26AP]

——— making appropriations to address heroin and opioid drug abuse epidemic (see H.R. 4938), H901 [6FE]

——— prevent substance abuse and reduce demand for illicit narcotics (see S. 2789), S2485 [26AP] (see H.R. 5933), H4692 [23MY]

——— provide assistance to States and localities affected by the opioid epidemic and improve delivery of essential services to individuals with substance use disorders and their families (see S. 2700), S2261 [18AP] (see H.R. 5545), H3440 [18AP]

——— provide certain protections from civil liability for individuals prescribing or administering opioid overdose drugs (see S. 2981), S2924 [24MY] (see H.R. 4955), H902 [6FE]

——— provide for a comprehensive, multifaceted approach to preventing and treating opioid addiction (see H.R. 5531), H3395 [17AP]

——— provide for a technical expert panel to provide recommendations on reducing opioid use in the surgical setting and on best practices for pain management (see H.R. 5718), H3884 [9MY]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders (see S. 2317), S253 [17JA]

——— provide for delivery of a controlled substance by a pharmacy to an administering practitioner (see H.R. 5202), H1476 [7MR]

——— provide for opioid use disorder prevention, recovery, and treatment (see H.R. 6), H5151 [13JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), concur in Senate amendment (see H. Res. 1099), H9406 [28SE]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), consideration (see H. Res. 949), H5283 [19JN]

——— require awareness campaign regarding risk of abuse of prescription opioids if such drugs are not taken as prescribed to include information about dispensing options (see S. 2697), S2261 [18AP]

——— require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug (see H.R. 6576), H7722 [26JY] (see H. Con. Res. 146), H10511 [20DE]

——— require improved packaging and disposal methods with respect to certain drugs (see H.R. 5687), H3781 [7MY]

——— require retail sellers of opioids to verify identity of prospective purchaser and enter certain information about purchase into respective State’s prescription drug monitoring system (see H.R. 5219), H1501 [8MR]

——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising (see S. 2440), S1164 [15FE]

——— study and report on policy and regulatory changes that may have contributed to the opioid epidemic (see H.R. 5914), H4583 [22MY]

EPA: exempt from certain Clean Air Act requirements law enforcement agency incinerator units when used for the sole purpose of destroying contraband or household pharmaceuticals (see H.R. 6291), H5974 [28JN]

——— study the presence of pharmaceuticals and personal care products in sources of drinking water (see H.R. 5548), H3440 [18AP]

FDA: allow for detention, refusal, and destruction of certain drugs offered for importation (see H.R. 5752), H3928 [10MY]

——— amend policies relative to postapproval study requirements for certain controlled substances (see H.R. 5811), H3976 [15MY]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (see S. 2315), S253 [17JA] (see H.R. 5333), H1698 [19MR] (see H.R. 7328), H10335 [19DE]

——— consider potential for misuse and abuse when determining whether to approve certain drugs (see H.R. 5803), H3976 [15MY]

——— deter opioid abuse and addiction through development of high-quality, evidence-based opioid analgesic prescribing guidelines (see H.R. 6133), H5283 [19JN]

——— encourage development of priority antimicrobial products through award of a transferable exclusivity extension period (see H.R. 6294), H5975 [28JN]

——— ensure valid generic drugs may enter the market by removing generic drug exclusivity period from any generic company that enters into pay-for-delay settlements with brand-name drug manufacturers (see S. 2476), S1286 [28FE]

——— establish Prescription Drug and Medical Device Price Review Board (see H.R. 5739), H3885 [9MY]

——— expand conditional approval pathway for more animal drugs (see H.R. 5599), H3505 [24AP]

——— hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (see S. 2691), S2218 [17AP] (see H.R. 5782), H3935 [11MY]

——— modify outdated drug labels to reflect new evidence relevant to the drug and its use (see S. 3519), S6355 [27SE]

——— prevent inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and provide incentives for drug innovation (see S. 3738), S7431 [11DE] (see H.R. 7251), H10102 [11DE]

——— provide for accelerated approval of non-opioid or non-addictive pain medications and treatments for substance use disorders (see S. 2669), S2141 [16AP]

——— provide greater oversight over advertising and other promotion materials for opioid drugs to ensure that such materials do not mislead consumers and exacerbate existing crisis (see S. 3420), S6059 [6SE]

——— require guidance on consideration of claims of opioid sparing and on conditions under which to consider misuse and abuse of drugs in making certain determinations for safety (see S. 2665), S2120 [12AP]

——— require label of drugs with an increased risk of suicide or depression to prominently detail those side effects (see H.R. 6717), H7919 [6SE]

——— require manufacturers of drugs to post names of countries in which their drugs are manufactured on their Internet websites (see S. 3105), S4343 [21JN]

——— require review of durations of use of approved indications of medically-important antibiotics labeled for use in animals (see S. 3099), S4281 [20JN]

——— require risk evaluation and mitigation strategy communication plans provide information on State and Federal regulation of controlled substances including the option to partially fill a prescription (see S. 2608), S1947 [22MR]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (see S. 3428), S6142 [12SE]

——— shorten exclusivity period for brand name biological products (see H.R. 6577), H7722 [26JY]

——— strengthen authorities to address counterfeit drugs, illegal and synthetic opioids, and opioid-like substances (see H.R. 5228), H1501 [8MR]

Federal aid programs: recognize essential benefit of Medicare and Social Security programs to current enrollees and strengthen such programs for future generations (see H. Res. 1026), H7687 [25JY]

Federal employees: remove limitations on Federal employment for individuals legally using marijuana according to laws of the State in which they reside (see H.R. 6589), H7722 [26JY]

FTC: issue rules to promote competition and help consumers save money by giving them the freedom to choose where they buy prescription pet medications (see S. 2651), S2075 [11AP] (see H.R. 5472), H3146 [11AP]

GAO: conduct a study and submit a report to Congress on best practices in use by Federal agencies and departments to reduce opioid usage following medical procedures (see H.R. 4903), H732 [30JA]

——— evaluate and report on inpatient and outpatient treatment capacity, availability, and needs (see S. 3048), S3601 [11JN]

——— study and report on State Medicaid agencies’ options relative to distribution of substance use disorder treatment medications (see S. 2909), S2835 [22MY]

——— study feasibility of establishing and maintaining automated system that tracks prescription drug prices (see H.R. 6593), H7722 [26JY]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (see H. Res. 905), H4283 [21MY]

Health care facilities: authorize hospitals to dispose of controlled substances on behalf of patients who die at the hospital (see H.R. 6205), H5580 [22JN]

Health care professionals: improve and expand training for future and current physicians and mid-level health care providers on treating pain and prescribing opioids (see H. Con. Res. 136), H8726 [13SE]

Insurance: cap prescription drug cost-sharing (see S. 3194), S4916 [11JY] (see H.R. 6340), H6111 [11JY]

——— ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (see S. 2554), S1735 [14MR] (see H.R. 6143), H5284 [19JN]

——— prohibit health insurance issuers, group health plans, Medicare Advantage organizations, and prescription drug plan sponsors from limiting drug price information a pharmacy may give to a consumer (see H.R. 6641), H7734 [31JY] (see H.R. 6733), H7941 [7SE]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by a health care provider (see S. 3742), S7509 [12DE]

Medicaid: cover protections for pregnant and post-partum women while receiving inpatient treatment for a substance use disorder (see H.R. 5789), H3975 [15MY]

——— evaluate access to services and treatment for substance use disorders, telehealth services, and remote patient monitoring for pediatric populations (see S. 2910), S2835 [22MY]

——— facilitate access to State prescription drug monitoring programs (see S. 2902), S2835 [22MY]

——— impose restrictions on opioid prescriptions (see H.R. 5635), H3705 [26AP]

——— improve access to care for pregnant and postpartum women receiving substance use disorder treatment in mental institutions (see S. 2922), S2835 [22MY]

——— prevent misclassification of drugs for purposes of the drug rebate program (see S. 3702), S7275 [4DE] (see H.R. 7223), H9767 [6DE]

——— provide extension of enhanced Federal medical assistance percentage for health homes for individuals with substance use disorders (see S. 3384), S5932 [23AU] (see H.R. 5810), H3976 [15MY]

——— provide requirements relative to use of qualified prescription drug monitoring programs and prescribing of certain controlled substances (see H.R. 5801), H3976 [15MY]

——— remove lifetime limits on medication-assisted treatment for substance use disorders (see S. 2898), S2835 [22MY]

——— require State plans to cover medication-assisted treatment (see H.R. 5802), H3976 [15MY]

——— sunset the limit on maximum rebate amount for single source drugs and innovator multiple source drugs (see H.R. 6642), H7734 [31JY]

Medicare: cover opioid treatment program services (see S. 2875), S2773 [17MY] (see H.R. 5080, 5083), H1226 [23FE] (see H.R. 5776), H3934 [11MY]

——— deliver a meaningful drug benefit and lower prescription drug prices (see H.R. 6575), H7722 [26JY]

——— encourage use of non-opioid analgesics for management of post-surgical pain (see H.R. 5809), H3976 [15MY]

——— ensure equitable payment for, and beneficiary access to, diagnostic radiopharmaceuticals under hospital outpatient prospective payment system (see H.R. 6948), H9150 [27SE]

——— establish Medicare for America program to provide comprehensive health insurance coverage for all U.S. residents (see H.R. 7339), H10336 [19DE]

——— establish part E public health plans available to everyone (see S. 2708), S2262 [18AP] (see H.R. 6117), H5200 [14JN]

——— exempt from certain criminal penalties the offering and use of certain pharmaceutical manufacturer copayment coupons to waive or reduce cost-sharing otherwise applied under the prescription drug benefit (see H.R. 6488), H7154 [24JY]

——— expand access to addiction treatment in federally qualified health centers and rural health clinics (see H.R. 5769), H3929 [10MY]

——— expand eligibility for medication therapy management programs to include certain individuals who are at risk for prescription drug abuse (see H.R. 5684), H3781 [7MY]

——— expand use of telehealth services for treatment of opioid use disorder and other substance use disorders (see S. 2901), S2835 [22MY]

——— identify and notify outlier prescribers of opioids (see S. 2920), S2835 [22MY] (see H.R. 5716), H3884 [9MY]

——— include screening for potential substance use disorders and a review of any current opioid prescriptions as part of the initial preventive physical examination and the annual wellness visit (see S. 2900), S2835 [22MY]

——— prevent growth rate cliff for out-of-pocket threshold under part D (see H.R. 6563), H7721 [26JY]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (see S. 2553), S1735 [14MR] (see H.R. 6144), H5284 [19JN]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), correction in enrollment (see S. Con. Res. 49), S6388 [28SE]

——— provide educational resources regarding opioid use and pain management as part of the ‘‘Medicare & You’’ handbook (see S. 2707), S2262 [18AP] (see H.R. 5685), H3781 [7MY]

——— provide for a combined part B and D drug out-of-pocket costs limitation (see H.R. 7001), H9406 [28SE]

——— provide for distribution of additional residency positions to help combat the opioid crisis (see S. 2843), S2678 [15MY] (see H.R. 5818), H3976 [15MY]

——— provide for electronic prior authorization for covered part D drugs (see S. 2908), S2835 [22MY] (see H.R. 4841), H553 [18JA]

——— provide for review and adjustment of payments under outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments (see H.R. 5778), H3935 [11MY] (see H.R. 6110), H5199 [14JN]

——— require Dept. of HHS to determine covered part D prescription drug prices for beneficiaries (see H.R. 6574), H7722 [26JY]

——— require Dept. of HHS to negotiate prices of prescription drugs (see H.R. 6505), H7685 [25JY]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation (see H.R. 5150), H1340 [1MR]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D (see H.R. 5958), H4728 [24MY]

——— require e-prescribing for coverage under part D of prescription drugs that are controlled substances (see S. 2460), S1243 [27FE]

——— require hospitals to provide information on acquisition costs for drugs in the 340B discount drug program and total revenues received by the hospital for such drugs (see S. 2453), S1243 [27FE]

——— require Medicare Advantage and part D prescription drug plans to include information on risks associated with opioids, coverage of certain nonopioid pain treatments, and safe disposal of prescription drugs (see H.R. 5775), H3934 [11MY]

——— require Medicare Advantage and part D prescription drug plans to provide information on safe disposal of prescription drugs that are controlled substances to certain enrolled individuals (see S. 3489), S6304 [25SE] (see H.R. 5714), H3884 [9MY]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries (see H.R. 5675), H3749 [3MY]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures (see H.R. 5773), H3934 [11MY]

——— require prescription drug plans to include information on adverse effects of opioid overutilization and of coverage of nonpharmacological therapies and nonopioid medications or devices used to treat pain (see H.R. 5686), H3781 [7MY]

——— require review of current opioid prescriptions for chronic pain and screening for opioid use disorder be included in initial preventive physical examinations (see H.R. 5798), H3975 [15MY]

——— require the Medicare Payment Advisory Commission to report on opioid payment, adverse incentives, and data (see H.R. 5723), H3884 [9MY]

——— study and report on feasibility of basing reimbursement rates for part B drugs and covered part D drugs on average prices in Organization for Economic Cooperation and Development member-states (see H.R. 6958), H9150 [27SE]

——— suspend payments by prescription drug plans and Medicare Advantage prescription drug plans pending investigation of credible allegations of fraud by pharmacies (see S. 3327), S5582 [1AU] (see H.R. 5676), H3749 [3MY]

Medicare/Medicaid: help end addictions and lessen substance abuse disorders (see S. 3120), S4368 [25JN]

——— promote ability of beneficiaries to access their personal medical claim data through a mobile health record application (see H.R. 7272), H10169 [12DE]

Meningitis B Awareness Day: observance (see H. Res. 842), H3506 [24AP]

National Women’s Health Week: recognize importance of goal to empower young women to make informed choices about sexual activity and take effective steps to protect against HIV (see S. Res. 507), S2679 [15MY]

NIH: conduct or support further comprehensive research for creation of a universal influenza vaccine (see S. 2438), S1164 [15FE] (see H.R. 5092), H1266 [26FE]

Office of National Drug Control Policy: track and review federally funded drug demand reduction activities (see S. 3380), S5932 [23AU]

Orphan Drug Act: affirm importance, commend life-saving accomplishments, and recognize need and continued support for research in development of therapies, treatments, and cures for rare diseases (see S. Res. 690), S7051 [15NO] (see H. Res. 1154), H9568 [16NO]

Patents: prohibit avoidance of drug patent reviews regardless of sovereign immunity claims facilitated by the transfer of patents to Indian tribes (see S. 2514), S1452 [7MR]

SEC: require certain additional disclosure by pharmaceutical companies relative to the Tax Cuts and Jobs Act (see S. 2885), S2773 [17MY]

Social Security: expand scope of transparency reporting requirements on ownership or investment interests of health care providers and others, and increase penalties for violating such requirements (see S. 3770), S7790 [18DE]

——— reform (see H.R. 7195), H9743 [29NO]

——— require drug and medical device companies to include information on payments made to physician assistants, nurse practitioners, and other advance practice nurses in certain transparency reports (see S. 2891), S2834 [22MY]

Taxation: authorize designation of additional taxable vaccines (see S. 3253), S5108 [19JY] (see H.R. 4993), H1074 [8FE]

——— include certain over-the-counter medical products as qualified medical expenses (see H.R. 6199), H5580 [22JN]

——— include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), consideration (see H. Res. 1012), H6648 [23JY]

——— prohibit deduction for prescription drug advertising and promotional expenses (see S. 2478), S1316 [1MR]

E-Mails

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: Advocates for Opioid Recovery (organization), H9252 [28SE]

Essays

State of the Union: Lillian Cazayoux, S606 [5FE]

Letters

Coordinated Response Through Interagency Strategy and Information Sharing (CRISIS) Act: Representative Frelinghuysen, Committee on Appropriations (House), H5322 [20JN]

——— Representative Gowdy, Committee on Oversight and Government Reform (House), H5321, H5322 [20JN]

——— Representative Nunes, Committee on Intelligence (House, Select), H5322 [20JN]

——— Representative Royce, Committee on Foreign Affairs (House), H5321 [20JN]

Know the Lowest Price Act: David Mitchell, Patients for Affordable Drugs, Inc., S2665 [15MY]

——— Karry K. La Violette, National Community Pharmacists Association, H8798 [25SE]

——— several health organizations, S2666 [15MY]

——— Tom O’Donnell, National Association of Chain Drug Stores, H8798 [25SE]

Opioid drug abuse prevention legislation: Representative Kevin Brady, Committee on Ways and Means (House), H5033, H5062, H5065 [12JN], H5238, H5241, H5248, H5252, H5256, H5257, H5260, H5262, H5264 [19JN]

——— Representative Walden, Committee on Energy and Commerce (House), H5033, H5062, H5065 [12JN], H5237, H5241, H5248, H5252, H5256, H5258, H5260, H5262, H5264 [19JN]

Overdose Prevention and Patient Safety Act: Partnerhship To Amend 42 CFR Part 2 (organization), H5332 [20JN]

——— several organizations, H5331 [20JN]

Patient Right To Know Drug Prices Act: David Mitchell, Patients for Affordable Drugs, Inc., S2665 [15MY]

——— Karry K. La Violette, National Community Pharmacists Association, H8798 [25SE]

——— Saul Levin, American Psychiatric Association, H8798 [25SE]

——— several health organizations, S2666 [15MY]

——— Thomas E. Menighan, American Pharmacists Association, S2665 [15MY]

Right To Try Act: Andrew McFadyen, Isaac Foundation, H1740 [21MR]

——— several organizations, H4358 [22MY]

Securing Opioids and Unused Narcotics With Deliberate (SOUND) Disposal and Packaging Act: William Simpson, DisposeRX, Inc., H5236 [19JN]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: Carol Keehan, Catholic Health Association of the U.S., H9252 [28SE]

——— Corporate Health Care Coalition, H9250 [28SE]

——— James A. Klein, American Benefits Council, H9251 [28SE]

——— Peter Morris, Alex Dodd, David White, Jay Higham, and John Steinbrun, Opioid Treatment Program Consortium, H5561 [22JN]

——— several organizations, H9253 [28SE]

——— Suzanne P. Clark, U.S. Chamber of Commerce, H9252 [28SE]

——— Tom Van Coverden, National Association of Community Health Centers, H9251 [28SE]

Lists

Organizations opposed to H.R. 5247, Right To Try Act, H1525 [13MR], H1742 [21MR]

Organizations supporting H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H9243 [28SE]

Messages

Budget of the U.S. Government for Fiscal Year 2019: President Trump, S870 [12FE], H1080 [13FE]

Motions

Dept. of HHS: ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), H5333 [20JN]

Drugs: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), H1746 [21MR]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), H5567 [22JN]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), H4363 [22MY]

Press releases

Know the Lowest Price Act: CVS Health Corp., S2666 [15MY]

——— Express Scripts Holding Co., S2666 [15MY]

Patient Right To Know Drug Prices Act: CVS Health Corp., S2666 [15MY]

——— Express Scripts Holding Co., S2666 [15MY]

——— Pharmaceutical Care Management Association, S2666 [15MY]

Remarks in House

Barton, Representative: appreciation of opportunity to serve, H10098–H10101 [11DE]

Business and industry: impact of pharmaceutical industry lobbyists and political contributions on prescription drug prices, H4592 [23MY]

CDC: carry out certain activities to prevent controlled substances overdoses (H.R. 5812), H5071–H5074 [12JN]

Centers for Medicare & Medicaid Services: provide for an action plan to prevent opioid addictions and enhance access to medication-assisted treatment (H.R. 5590), H5247–H5249 [19JN]

Committee on Foreign Affairs (House): Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations hearing on Global Health Supply Chain Management—Lessons Learned and Ways Forward, E682 [18MY]

Consumers: implement strategy to reduce prescription drug prices, H3867, H3868 [9MY], H3889 [10MY]

DEA: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment, H9248 [28SE]

——— allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (H.R. 5483), H5060, H5061 [12JN], E1537 [16NO]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (H.R. 4079), E888 [21JN]

——— develop training materials covering circumstances when a pharmacist may decline to fill a prescription due to suspicion the prescription is fraudulent, forged, or indicative of abuse (H.R. 4275), H5066, H5067 [12JN]

——— report on the sale of lawful and unlawful controlled substance analogues over the Internet, H5218 [15JN]

Democratic Party: national agenda, H8176 [13SE], E1335 [28SE]

Dept. of Defense: monitor medication prescribing practices for treatment of post-traumatic stress disorder, H4565 [22MY]

Dept. of HHS: amend and reauthorize National All Schedules Prescription Electronic Reporting (NASPER) Grant Program, H3436 [18AP]

——— appoint a Federal Coordinator to coordinate opioid abuse reduction programs, serve as a liaison to State and local opioid reduction activities, and establish an electronic database on opioid abuse information, H9246 [28SE]

——— appoint a Federal Coordinator to coordinate opioid abuse reduction programs, serve as a liaison to State and local opioid reduction activities, and establish an electronic database on opioid abuse information (H.R. 4284), H5034–H5036 [12JN]

——— appropriate funds for State Targeted Response to the Opioid Crisis Grants (H.R. 3495), H5110 [13JN]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments (H.R. 5197), H5067–H5069 [12JN], H5157 [14JN], E975 [6JY]

——— conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for certain Medicare enrollees (H.R. 5582), H5061–H5063 [12JN]

——— develop guidance on pain management and prevention of opioid use disorder for hospitals receiving payments under Medicare (H.R. 5774), H5254–H5256 [19JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), H5325–H5335 [20JN], E876 [20JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), consideration (H. Res. 949), H5294–H5304 [20JN], E901 [22JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), motion to recommit, H5334, H5335 [20JN]

——— establish a grant program to create comprehensive opioid recovery centers (H.R. 5327), H3434 [18AP], H5026, H5055–H5057 [12JN]

——— issue guidance relative to expedited approval of certain drugs, H5297 [20JN], H5512, H5516–H5518 [22JN]

——— issue guidelines for prescribing naloxone, H5565, H5566 [22JN]

——— nullify certain contractual provisions prohibiting or penalizing a pharmacist’s disclosure of availability of equivalent alternative drugs or methods of purchasing less expensive drugs (H.R. 5343), H8796 [25SE]

——— provide for opioid quality measures development and a technical expert panel on reducing surgical setting opioid use and data collection on perioperative opioid use (H.R. 5774), H5254–H5256 [19JN]

——— provide grants for eligible entities to provide technical assistance to outlier prescribers of opioids (H.R. 5796), H5237–H5239 [19JN]

——— provide greater transparency of discounts provided by drug manufacturers by requiring Pharmacy Benefit Managers to reimburse community pharamacists at the same rate as high volume box stores, H9541 [16NO]

——— provide research on, and recommendations for, opioid prescribing practices for pregnant women, H5564, H5565 [22JN]

——— provide research on, and recommendations for, opioid prescribing practices for pregnant women (H.R. 5646), H3710 [27AP]

——— report on extent to which certain Medicare Advantage plans include supplemental health care benefits designed to treat or prevent substance use disorders, H5252, H5253 [19JN]

——— require prescribers to complete continuing medical education courses on potential dangers and risks of prescribing opioids (H.R. 5581), H3589 [26AP]

——— survey organizations that provide substance use treatment services and submit plan to Congress to appropriate resources to address inadequacies in services or funding identified in survey, H5566, H5567 [22JN]

——— update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling (H.R. 5473), H5030–H5032 [12JN]

Dept. of Justice: establish a national pharmaceutical stewardship program to facilitate collection and disposal of prescription medications (H.R. 4199), H3825 [8MY]

——— reauthorize Comprehensive Opioid Abuse Grant Program (H.R. 6029), H5121–H5123 [13JN]

Dept. of Labor: establish an Advisory Committee on Opioids and the Workplace (H.R. 5892), H5129–H5131 [13JN], H5156 [14JN]

Dept. of Veterans Affairs: create an opioid abuse health care kit for community health centers, H4986, H4987 [8JN]

——— ensure health care providers at VA medical facilities complete a continuing education course in pain management, H4987 [8JN]

——— enter into memorandum of understanding with a national network of State-based prescription monitoring programs under which departmental health care providers shall query such network, H4044 [16MY]

——— enter into memorandum of understanding with a national network of State-based prescription monitoring programs under which departmental health care providers shall query such network (H.R. 3832), H4250, H4251 [21MY]

——— improve Medical Surgical Prime Vendor program by using multiple regional prime vendors and medical professionals with relevant expertise to develop the medical-surgical formulary, H9800 [10DE]

——— improve Medical Surgical Prime Vendor program by using multiple regional prime vendors and medical professionals with relevant expertise to develop the medical-surgical formulary (H.R. 5418), H4257, H4258 [21MY]

Drugs: address fentanyl abuse epidemic, E1222 [7SE]

——— address opioid drug abuse epidemic by securing the southern border, H5667 [26JN], H10326, H10327 [19DE]

——— address prescription opioid and heroin abuse, H3432–H3436 [18AP], H3565–H3567 [25AP], H5026, H5028 [12JN], H5099, H5102, H5103, H5105, H5112, H5113, H5140 [13JN], H5156, H5157, H5158, H5159, H5161, H5162, H5163, H5186 [14JN], H5221 [15JN], H5230 [19JN], H5663, H5664 [26JN], H5755 [27JN], H7692 [26JY]

——— authority of non-physician providers to prescribe buprenorphine for opioid use disorders, H5297 [20JN]

——— authorize employees of a hospice program to handle controlled substances in the residence of a deceased hospice patient to assist in disposal (H.R. 5041), H5043–H5045 [12JN], H5163 [14JN]

——— authorize evidence based report analyzing current marijuana policies and their effects on communities, H6637 [23JY]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), H1521–H1529, H1530 [13MR], H1738–H1750 [21MR]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), consideration (H. Res. 787), H1704–H1712 [20MR]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), motion to recommit, H1747, H1748 [21MR]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, enable medicinal research, and allow prescription to veterans, H3501–H3503 [24AP]

——— establish an interagency task force to improve Federal response to families impacted by substance abuse disorders (H.R. 5891), H5127–H5129 [13JN], H5156 [14JN]

——— increase State funding for response to opioid misuse crisis and research on addiction and pain relative to substance misuse crisis (H.R. 4501), H5299 [20JN]

——— making appropriations to address heroin and opioid drug abuse epidemic, H607 [21JA], H2031 [22MR]

——— making appropriations to address heroin and opioid drug abuse epidemic (H.R. 4938), H792, H793 [6FE]

——— prescription drug prices, E1325 [27SE]

——— prohibit expansion of classes of health care workers who are authorized to dispense narcotics for narcotic treatment, H5561, H5562 [22JN]

——— provide access to medication-assisted treatment programs to reduce opioid addiction overdoses and relapses, H5522 [22JN]

——— provide assistance to States and localities affected by the opioid epidemic and improve delivery of essential services to individuals with substance use disorders and their families (H.R. 5545), H5113 [13JN], H5323 [20JN]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, H5512, H5514 [22JN]

——— provide for additional residency positions to help combat opioid crisis, increase funding for opioid abuse crisis, and prohibit delays of generic drugs and biosimilar biological products, H5570 [22JN], E905 [25JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), H5380 [21JN], H5511–H5572 [22JN], H5755 [27JN], H9553 [16NO], E902 [22JN], E950 [28JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), concur in Senate amendment (H. Res. 1099), H9156, H9174–H9255 [28SE]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), consideration (H. Res. 949), H5294–H5304 [20JN], E901 [22JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), motion to recommit, H5570 [22JN], E905 [25JN]

——— require FDA guidance relative to investigational drug use by eligible patients, provide liability protection for facilitators of investigational treatments and increase transparency of number of such treatments, H1747, H1748 [21MR]

——— require improved packaging and disposal methods with respect to certain drugs (H.R. 5687), H5234–H5237 [19JN], E904 [22JN]

Economy: national objectives priority assignments, H3497 [24AP], H3586 [26AP]

Ellenville, NY: tribute to Ellenville Regional Hospital for initiative to combat opioid abuse, E1437 [23OC]

FDA: allow for detention, refusal, and destruction of certain drugs offered for importation (H.R. 5752), H5117–H5119 [13JN]

——— amend policies relative to postapproval study requirements for certain controlled substances (H.R. 5811), H5243, H5244 [19JN]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 5333), H6227–H6237 [16JY]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 7328), H10366–H10393 [20DE]

——— deter opioid abuse and addiction through development of high-quality, evidence-based opioid analgesic prescribing guidelines, H5563, H5564 [22JN]

——— hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (S. 2691), H3588 [26AP]

——— improve expanded access program to allow patients access to experimental life-saving drugs, H4364, H4365 [22MY]

——— preserve effectiveness of medically important antimicrobials used in treatment of animal diseases in order to minimize development of antibiotic-resistant bacteria (H.R. 1587), H3825 [8MY]

——— strengthen authorities to address counterfeit drugs, illegal and synthetic opioids, and opioid-like substances (H.R. 5228), H5049–H5052 [12JN], H5118 [13JN], E972 [6JY]

FTC: ensure mergers involving pharmaceutical companies do not lead to increases in prescription drug prices, H3856, H3857 [9MY]

GAO: study feasibility of establishing and maintaining automated system that tracks prescription drug prices (H.R. 6593), E1096 [26JY]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (H.R. 878), H685 [30JA], H1647 [15MR]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), H485 [18JA], H4355–H4366 [22MY], H4682 [23MY], E751 [29MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (H. Res. 905), H4292–H4301 [22MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), motion to recommit, H4364, H4365 [22MY]

——— national policy to provide health care and reform insurance procedures, H7815 [4SE], H10093–H10095 [11DE]

House of Representatives: legislative priorities, H6566 [19JY]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), H8795–H8799 [25SE]

——— prohibit health insurance issuers, group health plans, Medicare Advantage organizations, and prescription drug plan sponsors from limiting drug price information a pharmacy may give to a consumer (H.R. 6733), H8796 [25SE]

Medicaid: prevent misclassification of drugs for purposes of the drug rebate program, H10050, H10051 [11DE]

——— provide requirements relative to use of qualified prescription drug monitoring programs and prescribing of certain controlled substances (H.R. 5801), H5245–H5247 [19JN]

Medicare: cover opioid treatment program services, H5520 [22JN]

——— eliminate gap in coverage of prescription drug benefit, H1078 [13FE]

——— encourage use of non-opioid analgesics for management of post-surgical pain, H5512, H5513, H5514 [22JN]

——— establish Universal Medicare Program to provide comprehensive health insurance coverage for all U.S. residents (S. 1804), H9808 [10DE]

——— expand access to addiction treatment in federally qualified health centers and rural health clinics, H5252, H5253 [19JN]

——— expand eligibility for medication therapy management programs to include certain individuals who are at risk for prescription drug abuse, H5260, H5261 [19JN]

——— identify and notify outlier prescribers of opioids, H5260, H5261 [19JN]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), H8796–H8801 [25SE]

——— provide educational resources regarding opioid use and pain management as part of the ‘‘Medicare & You’’ handbook (H.R. 5685), H5064–H5066 [12JN]

——— provide for electronic prior authorization for covered part D drugs, H5260, H5261 [19JN]

——— provide for review and adjustment of payments under outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments, E870 [20JN]

——— provide for review and adjustment of payments under outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments (H.R. 6110), H5249–H5254 [19JN], E870 [20JN]

——— require e-prescribing for coverage under part D of prescription drugs that are controlled substances, H5512, H5514 [22JN]

——— require Medicare Advantage and part D prescription drug plans to include information on risks associated with opioids, coverage of certain nonopioid pain treatments, and safe disposal of prescription drugs (H.R. 5775), H5256–H5258 [19JN], E877 [20JN]

——— require Medicare Advantage and part D prescription drug plans to provide information on safe disposal of prescription drugs that are controlled substances to certain enrolled individuals, H5258 [19JN], E877 [20JN]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, H5520 [22JN]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures, E902 [22JN]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures (H.R. 5773), H5103 [13JN], H5258–H5261 [19JN]

——— require prescription drug plans to include information on adverse effects of opioid overutilization and of coverage of nonpharmacological therapies and nonopioid medications or devices used to treat pain, H5257, H5258 [19JN], E877 [20JN]

——— require review of current opioid prescriptions for chronic pain and screening for opioid use disorder be included in initial preventive physical examinations, H5514 [22JN]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries, H1647 [15MR]

——— require the Medicare Payment Advisory Commission to report on opioid payment, adverse incentives, and data (H.R. 5723), H4270 [21MY], H5264, H5265 [19JN]

——— suspend payments by prescription drug plans and Medicare Advantage prescription drug plans pending investigation of credible allegations of fraud by pharmacies (H.R. 5676), H5261–H5264 [19JN], E904 [22JN]

Medicare Payment Advisory Commission: report on opioid payment, adverse incentives, and tracking and monitoring data, H9553 [16NO]

Meningitis B Awareness Day: observance (H. Res. 842), H3458 [24AP]

National Association of Chain Drug Stores: tribute to annual RxIMPACT Day on Capitol Hill, E251 [5MR]

National Prescription Drug Take Back Day: observance, H3765 [7MY]

National Prescription Drug Take-Back Day: observance, H3689, H3690, H3691 [26AP]

Nobel Prize: recognition of Jim Allison for medicine, E1480 [30OC]

Office of National Drug Control Policy: High Intensity Drug Trafficking Area program funding, H6534 [18JY]

——— reauthorize, redesignate as Office of National Drug Control, and enhance authorities to improve Federal drug control efforts (H.R. 5925), H5304–H5325 [20JN]

Palm Beach County, FL: tribute to fight against opioid drug abuse epidemic, E144 [6FE]

Pharmaceutical industry: reform, H3988 [16MY]

Republican Party: national agenda, H7145 [24JY]

Safety: support antibiotic stewardship programs to ensure proper prescription and administration of antibiotics, E1533 [16NO]

Taxation: establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (H.R. 3254), H5140 [13JN]

——— include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), H6572 [19JY], H7095 [24JY], H7651–H7658 [25JY]

——— include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), consideration (H. Res. 1012), H7100–H7106 [24JY]

World Antibiotic Awareness Week: observance, E1533 [16NO]

World Pharmacists Day: observance, H9139 [27SE]

Remarks in Senate

Azar, Alex M., II: suitability to be Sec. of HHS relative to history of raising prescription drug prices while serving as drug company executive, S458 [23JA]

Business and industry: improve access to affordable prescription drugs, S7220 [29NO]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (S. 124), S7220 [29NO], S7889 [19DE]

Committee on Health, Education, Labor, and Pensions (Senate): call for investigation of drug companies’ knowledge about addictive qualities of drugs they manufacture, S629 [6FE]

Committee on the Judiciary (Senate): accomplishments, S7982–S7984 [20DE]

Comprehensive Addiction and Recovery Act: reauthorize and expand, S6050 [6SE], S6126 [12SE], S6170 [17SE]

——— reauthorize and expand (S. 2456), S1245–S1247 [27FE], S2471 [26AP], S2573 [9MY], S3597 [11JN], S7176 [28NO]

Congress: accomplishments of the 115th Congress, S2889 [24MY], S2973 [5JN], S6954–S6956 [14NO]

Consumers: implement strategy to reduce prescription drug prices, S2601 [10MY], S2691 [16MY]

DEA: allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals, S6472 [3OC]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (S. 2659), S2105 [12AP]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse, S6174 [17SE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders, S6471 [3OC]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 2838), S2680 [15MY], S3596 [11JN]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (S. 2561), S1766 [15MR]

Dept. of HHS: allow personal importation of safe and affordable drugs from approved pharmacies in Canada (S. 92), S7221 [29NO]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments (S. 2516), S2067 [11AP]

——— conduct a study on the changes in prices of prescription drugs, S5879 [23AU]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records, S6472 [3OC]

——— establish a grant program to create comprehensive opioid recovery centers, S6164 [17SE], S6471 [3OC]

——— establish community action opioid response grant program (S. 2636), S2105 [12AP]

——— establish grant program within the Substance Abuse and Mental Health Services Administration to create peer support recovery networks (S. 2657), S2105 [12AP]

——— make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants and expand use to include methamphetamine abuse, S6166 [17SE]

——— require drug manufacturers to publicly justify unnecessary price increases (S. 1348), S5880, S5881 [23AU]

——— require Substance Abuse and Mental Health Services Administration to report to Congress on barriers to providing medication-assisted drug treatment to youths, S6161 [17SE]

Diseases and disorders: cancer research funding, S6705 [9OC]

Drugs: address opioid drug abuse epidemic by securing the southern border, S7393 [11DE], S7554–S7556 [13DE]

——— address prescription opioid and heroin abuse, S2066 [11AP], S2414 [25AP], S2463, S2469–S2472 [26AP], S2909–S2911 [24MY], S2973 [5JN], S3873, S3874 [13JN], S4491, S4492 [27JN], S5049 [18JY], S5101–S5103 [19JY], S5326 [25JY], S5603–S5606 [15AU], S5746–S5748 [21AU], S6209 [18SE], S6796 [11OC], S7175–S7178 [28NO], S7573–S7575 [13DE], S7841 [19DE]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), S1981, S1982 [22MR], S1994 [9AP]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur, or with another eligible illness (H.R. 5247), unanimous-consent request, S1981 [22MR]

——— extend authority of nurse practitioners to provide medication-assisted treatment for opioid use disorders, S6163 [17SE]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment, S6164 [17SE]

——— making appropriations to address heroin and opioid drug abuse epidemic, S146–S148 [11JA], S280 [18JA], S321 [19JA], S629 [6FE], S812–S815 [8FE], S887 [12FE], S6210 [18SE]

——— prevent regulatory oversight from disrupting ability of emergency medical personnel to administer certain controlled substances (S. 916), S2882–S2884 [23MY]

——— prevent substance abuse and reduce demand for illicit narcotics, S6120 [12SE]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, S6162 [17SE], S6463, S6469 [3OC]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), S4376 [25JN], S4380 [26JN], S6048–S6050 [6SE], S6116–S6121, S6126, S6149 [12SE], S6159–S6170, S6172–S6178 [17SE], S6198, S6210, S6215–S6217, S6218 [18SE], S7177 [28NO]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), House amendment, S6432–S6436 [2OC], S6456, S6459, S6463, S6467, S6468–S6474, S6477–S6484, S6489, S6491 [3OC], S6796–S6798 [11OC]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), unanimous-consent agreement, S6105 [6SE], S6457 [3OC]

——— require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug, S5406–S5409 [26JY], S5736 [21AU], S5809–S5811 [22AU], S5882–S5884 [23AU], S7221 [29NO]

——— Senate investigation of Kaléo, Inc., pricing of naloxone auto-injector to reverse effects of overdoses, S7574 [13DE]

——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising, S3596 [11JN], S6173 [17SE]

FDA: prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (S. 974), S807 [8FE], S5881 [23AU], S7221 [29NO]

——— provide for accelerated approval of non-opioid or non-addictive pain medications and treatments for substance use disorders, S6470 [3OC]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (S. 3428), S6162 [17SE], S6463 [3OC]

Health: emergency medical services resources funding, S4841 [9JY]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), S2664–S2667 [15MY], S6164, S6170–S6173, S6175, S6176, S6178 [17SE], S7221 [29NO]

——— ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), unanimous-consent agreement, S6105 [6SE]

——— ensure that self-insured group health insurance plans that are exempt from State regulations do not prohibit pharmacy providers from providing certain information to enrollees, S6178 [17SE]

——— limit application of provision to prohibit pharmacy providers from providing certain information to enrollees to self-insured group health plans, S6171, S6172 [17SE]

Medicaid: prevent misclassification of drugs for purposes of the drug rebate program (S. 3702), S7339 [6DE]

Medicare: establish part E public health plans available to everyone (S. 2708), S2265 [18AP]

——— expand use of telehealth services for treatment of opioid use disorder and other substance use disorders, S6210 [18SE]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), S2664–S2667 [15MY], S6033 [4SE], S6173 [17SE]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), correction in enrollment (S. Con. Res. 49), S6375 [28SE]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (S. 41), S5880 [23AU]

National Prescription Drug Take-Back Day: observance, S2464 [26AP]

Supreme Court: decision in Whole Woman’s Health v. Hellerstedt relative to Texas law restricting access to abortion services, S4485–S4488, S4493 [27JN]

Taxation: establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (S. 523), S6473 [3OC]

Trump, President: evaluation of administration, S2658 [15MY]

Reports

Opioid Crisis in Illinois—Data and the State’s Response: Illinois Dept. of Human Services, H5169 [14JN]

Reports filed

Abuse Deterrent Access Act: Committee on Energy and Commerce (House) (H.R. 5582) (H. Rept. 115–721), H5020 [8JN]

Access to Increased Drug Disposal Act: Committee on the Judiciary (Senate) (S. 2645), S4035 [19JN]

Combating Opioid Abuse for Care in Hospitals (COACH) Act: Committee on Ways and Means (House) (H.R. 5774) (H. Rept. 115–762), H5283 [19JN]

Commit to Opioid Medical Prescriber Accountability and Safety for Seniors (COMPASS) Act: Committee on Energy and Commerce (House) (H.R. 5716) (H. Rept. 115–740), H5092 [12JN]

Consideration of H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: Committee on Rules (House) (H. Res. 949) (H. Rept. 115–766), H5283 [19JN]

Consideration of H.R. 4456, Alleviating Stress Test Burdens To Help Investors Act and H.R. 5247, Right To Try Act: Committee on Rules (House) (H. Res. 787) (H. Rept. 115–613), H1697 [19MR]

Consideration of H.R. 6082, Overdose Prevention and Patient Safety Act: Committee on Rules (House) (H. Res. 949) (H. Rept. 115–766), H5283 [19JN]

Consideration of H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act: Committee on Rules (House) (H. Res. 1012) (H. Rept. 115–861), H6648 [23JY]

Consideration of S. 204, Right To Try Act: Committee on Rules (House) (H. Res. 905) (H. Rept. 115–698), H4283 [21MY]

Coordinated Response Through Interagency Strategy and Information Sharing (CRISIS) Act: Committee on Oversight and Government Reform (House) (H.R. 5925) (H. Rept. 115–767), H5361 [20JN]

Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act: Committee on the Judicary (Senate) (S. 974), S4343 [21JN]

Every Prescription Conveyed Securely Act: Committee on Energy and Commerce (House) (H.R. 3528) (H. Rept. 115–748), H5092 [12JN]

Expanding Oversight of Opioid Prescribing and Payment Act: Committee on Ways and Means (House) (H.R. 5723) (H. Rept. 115–760), H5283 [19JN]

Helping To End Addiction and Lessen Substance Use Disorders (HEAL) Act: Committee on Finance (Senate) (S. 3120) (S. Rept. 115–284), S4368 [25JN]

Medicaid Coverage Protections for Pregnant and Post-Partum Women While Receiving Inpatient Treatment for a Substance Use Disorder: Committee on Energy and Commerce (House) (H.R. 5789) (H. Rept. 115–730), H5091 [12JN]

Medicaid Health Homes for Opioid-Use-Disorder Medicaid Enrollees Encouraged (Medicaid Health HOME) Act: Committee on Energy and Commerce (House) (H.R. 5810) (H. Rept. 115–727), H5091 [12JN]

Medicaid Pharmaceutical Home Act: Committee on Energy and Commerce (House) (H.R. 5808) (H. Rept. 115–726), H5091 [12JN]

Medicaid Providers Are Required To Note Experiences in Record Systems To Help In-Need Patients (Medicaid PARTNERSHIP) Act: Committee on Energy and Commerce (House) (H.R. 5801) (H. Rept. 115–725), H5091 [12JN]

Medicare and Opioid Safe Treatment (MOST) Act: Committee on Ways and Means (House) (H.R. 5776) (H. Rept. 115–764), H5283 [19JN]

Medicare Clear Health Options in Care for Enrollees (Medicare CHOICE) Act: Committee on Energy and Commerce (House) (H.R. 5686) (H. Rept. 115–741), H5092 [12JN]

Medicare Opioid Safety Education Act: Committee on Energy and Commerce (House) (H.R. 5685) (H. Rept. 115–715), H5020 [8JN]

Opioid Addiction Action Plan Act: Committee on Energy and Commerce (House) (H.R. 5590) (H. Rept. 115–746), H5092 [12JN]

Opioid Crisis Response Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2680), S2517 [7MY]

Opioid Quota Reform Act: Committee on the Judiciary (Senate) (S. 2535), S4035 [19JN]

Opioid Screening and Chronic Pain Management Alternatives for Seniors Act: Committee on Energy and Commerce (House) (H.R. 5798) (H. Rept. 115–739), H5092 [12JN]

Opportunities To Provide for Illicit Opioid Interdiction and Detection (OPIOID) Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 3047) (S. Rept. 115–353), S6924 [13NO]

Overdose Prevention and Patient Safety Act: Committee on Energy and Commerce (House) (H.R. 5795) (H. Rept. 115–724), H5091 [12JN]

Over-the-Counter Drug Safety, Innovation, and Reform Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2315), S2642 [14MY]

Over-the-Counter Monograph Safety, Innovation, and Reform Act: Committee on Energy and Commerce (House) (H.R. 5333) (H. Rept. 115–827), H6262 [16JY]

Patient Right To Know Drug Prices Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2554), S5516 [31JY]

Postoperative Opioid Prevention Act: Committee on Energy and Commerce (House) (H.R. 5809) (H. Rept. 115–753), H5151 [13JN]

Preventing Addiction for Susceptible Seniors (PASS) Act: Committee on Ways and Means (House) (H.R. 5773) (H. Rept. 115–761), H5283 [19JN]

Preventing Drug Diversion Act: Committee on the Judiciary (Senate) (S. 2837), S4035 [19JN]

Protecting Seniors From Opioid Abuse Act: Committee on Energy and Commerce (House) (H.R. 5684) (H. Rept. 115–742), H5092 [12JN]

Providing Reliable Options for Patients and Educational Resources (PROPER) Act: Committee on Ways and Means (House) (H.R. 5775) (H. Rept. 115–763), H5283 [19JN]

Require Medicare Prescription Drug Plan Sponsors To Establish Drug Management Programs for At-Risk Beneficiaries: Committee on Energy and Commerce (House) (H.R. 5675) (H. Rept. 115–743), H5092 [12JN]

Responsible Education Achieves Care and Healthy Outcomes for Users’ Treatment (REACH OUT) Act: Committee on Energy and Commerce (House) (H.R. 5796) (H. Rept. 115–729), H5091 [12JN]

Restoring Access to Medication and Modernizing Health Savings Accounts Act: Committee on Ways and Means (House) (H.R. 6199) (H. Rept. 115–850), H6587 [19JY]

Standardizing Electronic Prior Authorization for Safe Prescribing Act: Committee on Energy and Commerce (House) (H.R. 4841) (H. Rept. 115–747), H5092 [12JN]

Stop Excessive Narcotics in Our Retirement (SENIOR) Communities Protection Act: Committee on Ways and Means (House) (H.R. 5676) (H. Rept. 115–759), H5283 [19JN]

Substance Abuse Prevention Act: Committee on the Judiciary (Senate) (S. 2789), S4035 [19JN]

Using Data To Prevent Opioid Diversion Act: Committee on the Judiciary (Senate) (S. 2838), S4035 [19JN]

Veterans Affairs Medical-Surgical Purchasing Stabilization Act: Committee on Veterans’ Affairs (House) (H.R. 5418) (H. Rept. 115–693), H4283 [21MY]

Veterans Opioid Abuse Prevention Act: Committee on Veterans’ Affairs (House) (H.R. 3832) (H. Rept. 115–684), H4241 [18MY]

Statements

Opioid Epidemic: Jean and Dave Duffy, H5171 [14JN]

Right To Try Act: Senator Johnson, H4360 [22MY]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: American Society of Addiction Medicine, H9252 [28SE]

——— National Association for Behavorial Healthcare, H9251 [28SE]

——— Simona Combi, First Focus Campaign for Children (organization), H9250 [28SE]

Texts of

H. Res. 787, consideration of H.R. 5247, Right To Try Act, H1704 [20MR]

H. Res. 905, consideration of S. 204, Right To Try Act, H4292 [22MY]

H. Res. 949, consideration of H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H5294 [20JN]

H. Res. 949, consideration of H.R. 6082, Overdose Prevention and Patient Safety Act, H5294 [20JN]

H. Res. 1012, consideration of H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act, H7100 [24JY]

H. Res. 1099, concur in Senate amendment to H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H9174–H9242 [28SE]

H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H5522–H5560 [22JN]

H.R. 3832, Veterans Opioid Abuse Prevention Act, H4250 [21MY]

H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act, H5066 [12JN]

H.R. 4284, Indexing Narcotics, Fentanyl, and Opioids (INFO) Act, H5034 [12JN]

H.R. 5041, Safe Disposal of Unused Medication Act, H5043 [12JN]

H.R. 5197, Alternatives to Opioids in the Emergency Department (ALTO) Act, H5067 [12JN]

H.R. 5228, Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now (SCREEN) Act, H5049–H5051 [12JN]

H.R. 5247, Right To Try Act, H1521 [13MR], H1738 [21MR]

H.R. 5327, Comprehensive Opioid Recovery Centers Act, H5055 [12JN]

H.R. 5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act, H6227–H6235 [16JY]

H.R. 5418, Veterans Affairs Medical-Surgical Purchasing Stabilization Act, H4257 [21MY]

H.R. 5473, Better Pain Management Through Better Data Act, H5031 [12JN]

H.R. 5483, Special Registration for Telemedicine Clarification Act, H5060 [12JN]

H.R. 5582, Abuse Deterrent Access Act, H5061 [12JN]

H.R. 5590, Opioid Addiction Action Plan Act, H5247 [19JN]

H.R. 5676, Stop Excessive Narcotics in Our Retirement (SENIOR) Communities Protection Act, H5261 [19JN]

H.R. 5685, Medicare Opioid Safety Education Act, H5064 [12JN]

H.R. 5687, Securing Opioids and Unused Narcotics With Deliberate (SOUND) Disposal and Packaging Act, H5234 [19JN]

H.R. 5723, Expanding Oversight of Opioid Prescribing and Payment Act, H5264 [19JN]

H.R. 5752, Stop Illicit Drug Importation Act, H5117 [13JN]

H.R. 5773, Preventing Addiction for Susceptible Seniors (PASS) Act, H5258 [19JN]

H.R. 5774, Combating Opioid Abuse for Care in Hospitals (COACH) Act, H5254 [19JN]

H.R. 5775, Providing Reliable Options for Patients and Educational Resources (PROPER) Act, H5256 [19JN]

H.R. 5796, Responsible Education Achieves Care and Healthy Outcomes for Users’ Treatment (REACH OUT) Act, H5237 [19JN]

H.R. 5801, Medicaid Providers Are Required To Note Experiences in Record Systems To Help In-Need Patients (Medicaid PARTNERSHIP) Act, H5245–H5247 [19JN]

H.R. 5811, amend FDA policies relative to postapproval study requirements for certain controlled substances, H5243 [19JN]

H.R. 5812, Creating Opportunities That Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies (CONNECTIONS) Act, H5071–H5073 [12JN]

H.R. 5891, Improving the Federal Response to Families Impacted by Substance Use Disorder Act, H5127 [13JN]

H.R. 5892, Dept. of Labor Advisory Committee on Opioids and the Workplace establishment, H5129 [13JN]

H.R. 5925, Coordinated Response Through Interagency Strategy and Information Sharing (CRISIS) Act, H5304–H5321 [20JN]

H.R. 6029, Reauthorizing and Extending Grants for Recovery From Opioid Use Programs (REGROUP) Act, H5121 [13JN]

H.R. 6082, Overdose Prevention and Patient Safety Act, H5325 [20JN]

H.R. 6110, Pain Management, Treatment, and Recovery Act, H5250–H5252 [19JN]

H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act, H7651–H7653 [25JY]

H.R. 7328, Pandemic and All-Hazards Preparedness and Advancing Innovation Act, H10366–H10391 [20DE]

S. 204, Right To Try Act, H4355 [22MY]

S. 916, Protecting Patient Access to Emergency Medications Act, S2882–S2884 [23MY]

S. 2535, Opioid Quota Reform Act, S1632 [12MR]

S. 2553, Know the Lowest Price Act, S6033 [4SE], H8799 [25SE]

S. 2554, Patient Right To Know Drug Prices Act, H8795 [25SE]

S. 2729, Addiction Prevention and Responsible Opioid Practices Act, S2343–S2346 [23AP]

S. 2789, Substance Abuse Prevention Act, S2487–S2490 [26AP]

S. Con. Res. 49, correction in enrollment of S. 2553, Know the Lowest Price Act, S6390 [28SE], H9412 [2OC]

S. Res. 507, recognize importance of goal of National Women’s Health Week to empower young women to make informed choices about sexual activity and take effective steps to protect against HIV, S2681 [15MY]

S. Res. 690, affirm importance and commend life-saving accomplishments of Orphan Drug Act, and recognize need and continued support for research in development of therapies, treatments, and cures for rare diseases, S7055 [15NO]